CO7160108A2 - Formulación de implantes de risperidona o paliperidona - Google Patents
Formulación de implantes de risperidona o paliperidonaInfo
- Publication number
- CO7160108A2 CO7160108A2 CO14285844A CO14285844A CO7160108A2 CO 7160108 A2 CO7160108 A2 CO 7160108A2 CO 14285844 A CO14285844 A CO 14285844A CO 14285844 A CO14285844 A CO 14285844A CO 7160108 A2 CO7160108 A2 CO 7160108A2
- Authority
- CO
- Colombia
- Prior art keywords
- risperidone
- composition
- weeks
- drug
- paliperidone
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title abstract 2
- 239000007943 implant Substances 0.000 title abstract 2
- 229960001057 paliperidone Drugs 0.000 title abstract 2
- 229960001534 risperidone Drugs 0.000 title abstract 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 abstract 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 235000014655 lactic acid Nutrition 0.000 abstract 2
- 239000004310 lactic acid Substances 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 239000011049 pearl Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170362.3A EP2529756B1 (en) | 2011-05-31 | 2012-05-31 | Risperidone and/or Paliperidone implant formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7160108A2 true CO7160108A2 (es) | 2015-01-15 |
Family
ID=46147376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14285844A CO7160108A2 (es) | 2012-05-31 | 2014-12-30 | Formulación de implantes de risperidona o paliperidona |
Country Status (32)
| Country | Link |
|---|---|
| EP (2) | EP2529756B1 (https=) |
| JP (1) | JP6367795B2 (https=) |
| KR (1) | KR101880716B1 (https=) |
| CN (1) | CN104363923A (https=) |
| AU (1) | AU2013269547B2 (https=) |
| BR (1) | BR112014029209A2 (https=) |
| CA (1) | CA2874765C (https=) |
| CL (1) | CL2014003216A1 (https=) |
| CO (1) | CO7160108A2 (https=) |
| CY (1) | CY1124369T1 (https=) |
| DK (2) | DK2529756T3 (https=) |
| EA (1) | EA031819B1 (https=) |
| ES (1) | ES2878112T3 (https=) |
| FI (1) | FI2854858T3 (https=) |
| HR (2) | HRP20260301T1 (https=) |
| IL (1) | IL235849B (https=) |
| IN (1) | IN2014DN10672A (https=) |
| LT (2) | LT2529756T (https=) |
| MA (1) | MA37664B1 (https=) |
| MX (1) | MX374955B (https=) |
| MY (1) | MY174999A (https=) |
| NZ (1) | NZ703321A (https=) |
| PH (1) | PH12014502667B1 (https=) |
| PL (2) | PL2529756T3 (https=) |
| PT (2) | PT2529756T (https=) |
| RS (1) | RS62059B1 (https=) |
| SG (1) | SG11201407961WA (https=) |
| SI (1) | SI2529756T1 (https=) |
| SM (1) | SMT202100448T1 (https=) |
| UA (1) | UA119430C2 (https=) |
| WO (1) | WO2013178812A1 (https=) |
| ZA (1) | ZA201409299B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| EP2529757B1 (en) * | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Paliperidone implant formulation |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| LT2394664T (lt) | 2010-05-31 | 2016-09-26 | Laboratorios Farmaceuticos Rovi, S.A. | Antipsichozinė injekcinė depozitinė kompozicija |
| PT2394663T (pt) | 2010-05-31 | 2021-11-26 | Farm Rovi Lab Sa | Composições para implantes biodegradáveis injectáveis |
| LT2529756T (lt) * | 2011-05-31 | 2021-07-26 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidono ir (arba) paliperidono implantų kompozicija |
| HK1220628A1 (zh) | 2013-03-11 | 2017-05-12 | Durect Corporation | 包含高粘度液体载体的可注射控制释放组合物 |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| CN104922085B (zh) * | 2015-06-01 | 2016-10-26 | 湖南赛沃药业有限公司 | 一种利培酮植入剂及其制备方法 |
| CN109589304A (zh) * | 2017-10-01 | 2019-04-09 | 万特制药(海南)有限公司 | 利培酮口服溶液及其制备方法 |
| US11689849B2 (en) | 2018-05-24 | 2023-06-27 | Nureva, Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| KR20260007295A (ko) | 2018-05-24 | 2026-01-13 | 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 | 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치 |
| US11690806B2 (en) | 2018-05-24 | 2023-07-04 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| PE20210047A1 (es) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| US12594236B2 (en) | 2021-07-16 | 2026-04-07 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| US12318387B2 (en) | 2021-07-16 | 2025-06-03 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
| AU2023281232A1 (en) | 2022-05-18 | 2024-10-24 | Laboratorios Farmacéuticos Rovi, S.A. | Prolonged-release injectable compositions for use in treatment with risperidone together with cyp2d6 enzyme inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1074923C (zh) | 1993-11-19 | 2001-11-21 | 詹森药业有限公司 | 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类 |
| US7658998B2 (en) * | 2003-01-22 | 2010-02-09 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| WO2005007122A2 (en) * | 2003-07-18 | 2005-01-27 | Oakwood Laboratories, L.L.C. | Polymer stabilization |
| JP2008509144A (ja) | 2004-08-04 | 2008-03-27 | アルザ・コーポレーシヨン | 上昇するゼロ次放出パターンを示す持続薬剤放出組成物、そのような組成物を製造する方法 |
| JP5315336B2 (ja) | 2007-04-19 | 2013-10-16 | 又欣 李 | 精神疾患治療用の新規化合物とその調剤及び使用 |
| DK2167039T3 (en) * | 2007-05-18 | 2017-01-09 | Durect Corp | Improved depot formulations |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| WO2009015828A1 (en) | 2007-07-27 | 2009-02-05 | Synthon B.V. | Paliperidone derivatives |
| BRPI0821408A2 (pt) | 2007-12-19 | 2015-06-16 | Janssen Pharmaceutica Nv | Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação |
| EP2485712A1 (en) | 2009-10-06 | 2012-08-15 | Ascendis Pharma A/S | Subcutaneous paliperidone composition |
| EP2529757B1 (en) * | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Paliperidone implant formulation |
| LT2394664T (lt) | 2010-05-31 | 2016-09-26 | Laboratorios Farmaceuticos Rovi, S.A. | Antipsichozinė injekcinė depozitinė kompozicija |
| PT2394663T (pt) * | 2010-05-31 | 2021-11-26 | Farm Rovi Lab Sa | Composições para implantes biodegradáveis injectáveis |
| LT2529756T (lt) * | 2011-05-31 | 2021-07-26 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidono ir (arba) paliperidono implantų kompozicija |
-
2012
- 2012-05-31 LT LTEP12170362.3T patent/LT2529756T/lt unknown
- 2012-05-31 SM SM20210448T patent/SMT202100448T1/it unknown
- 2012-05-31 DK DK12170362.3T patent/DK2529756T3/da active
- 2012-05-31 ES ES12170362T patent/ES2878112T3/es active Active
- 2012-05-31 EP EP12170362.3A patent/EP2529756B1/en active Active
- 2012-05-31 RS RS20210834A patent/RS62059B1/sr unknown
- 2012-05-31 PL PL12170362T patent/PL2529756T3/pl unknown
- 2012-05-31 SI SI201231933T patent/SI2529756T1/sl unknown
- 2012-05-31 PT PT121703623T patent/PT2529756T/pt unknown
-
2013
- 2013-05-31 CA CA2874765A patent/CA2874765C/en active Active
- 2013-05-31 BR BR112014029209A patent/BR112014029209A2/pt not_active Application Discontinuation
- 2013-05-31 DK DK13726003.0T patent/DK2854858T3/da active
- 2013-05-31 CN CN201380027927.8A patent/CN104363923A/zh active Pending
- 2013-05-31 WO PCT/EP2013/061320 patent/WO2013178812A1/en not_active Ceased
- 2013-05-31 SG SG11201407961WA patent/SG11201407961WA/en unknown
- 2013-05-31 MY MYPI2014703551A patent/MY174999A/en unknown
- 2013-05-31 KR KR1020147035300A patent/KR101880716B1/ko active Active
- 2013-05-31 JP JP2015514533A patent/JP6367795B2/ja active Active
- 2013-05-31 MX MX2014014483A patent/MX374955B/es active IP Right Grant
- 2013-05-31 HR HRP20260301TT patent/HRP20260301T1/hr unknown
- 2013-05-31 EP EP13726003.0A patent/EP2854858B1/en active Active
- 2013-05-31 AU AU2013269547A patent/AU2013269547B2/en active Active
- 2013-05-31 FI FIEP13726003.0T patent/FI2854858T3/fi active
- 2013-05-31 IN IN10672DEN2014 patent/IN2014DN10672A/en unknown
- 2013-05-31 PL PL13726003.0T patent/PL2854858T3/pl unknown
- 2013-05-31 NZ NZ703321A patent/NZ703321A/en unknown
- 2013-05-31 LT LTEPPCT/EP2013/061320T patent/LT2854858T/lt unknown
- 2013-05-31 UA UAA201414187A patent/UA119430C2/uk unknown
- 2013-05-31 EA EA201401346A patent/EA031819B1/ru unknown
- 2013-05-31 PT PT137260030T patent/PT2854858T/pt unknown
-
2014
- 2014-11-23 IL IL235849A patent/IL235849B/en active IP Right Grant
- 2014-11-26 CL CL2014003216A patent/CL2014003216A1/es unknown
- 2014-11-28 PH PH12014502667A patent/PH12014502667B1/en unknown
- 2014-12-16 MA MA37664A patent/MA37664B1/fr unknown
- 2014-12-17 ZA ZA2014/09299A patent/ZA201409299B/en unknown
- 2014-12-30 CO CO14285844A patent/CO7160108A2/es unknown
-
2021
- 2021-07-02 HR HRP20211057TT patent/HRP20211057T1/hr unknown
- 2021-07-16 CY CY20211100644T patent/CY1124369T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7160108A2 (es) | Formulación de implantes de risperidona o paliperidona | |
| CO7160109A2 (es) | Formulación de implantes de paliperidona | |
| CY1122793T1 (el) | Χλωριουχο αλας του tat-nr2b9c | |
| CY1122771T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων | |
| MX2018010805A (es) | Agentes antivirales contra la hepatitis b. | |
| CL2017000664A1 (es) | Micropartículas inyectables para la liberación hiper-localizada de agentes terapéuticos | |
| NI201000193A (es) | Formulaciones orales de análogos de citidina y métodos de uso de las mismas. | |
| CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa | |
| ECSP14013156A (es) | Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth2. | |
| CL2019000766A1 (es) | Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes. | |
| PH12017502149A1 (en) | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester | |
| BR112014009242A2 (pt) | nanossuspensão farmacêutica | |
| WO2014119985A3 (es) | Composición farmacéutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral | |
| CR20120290A (es) | Formulaciòn de liberaciòn sostenida | |
| CL2020000124A1 (es) | Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil. | |
| NI201400136A (es) | Compuestos d - aminoácidos para enfermedad hepática |